Where is GIPAP™ available?
Based on global medical and socio-economic eligibility criteria, GIPAP is accessible
to eligible patients in developing countries with minimal reimbursement capabilities
and where regulatory approval (or at least an import license) for Glivec has been
obtained and no generic versions of imatinib are available. In certain countries,
due to variations in healthcare systems and economies, Novartis has established
local public-private partnerships to enhance access to Glivec through local patient
assistance programs.